Expert opinion on drug delivery最新文献_第2页

Lipid vesicular nanocarriers for the management of atopic dermatitis: a paradigm shift in healing. 脂质囊泡纳米载体的管理特应性皮炎：在愈合的范式转变。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-10-10 DOI: 10.1080/17425247.2026.2696893

Manaswini Behera, Priyanka Mahale, Ravinder K Kaundal, Rahul Shukla

{"title":"Lipid vesicular nanocarriers for the management of atopic dermatitis: a paradigm shift in healing.","authors":"Manaswini Behera, Priyanka Mahale, Ravinder K Kaundal, Rahul Shukla","doi":"10.1080/17425247.2026.2696893","DOIUrl":"10.1080/17425247.2026.2696893","url":null,"abstract":"Introduction: Atopic dermatitis (AD) is a recurring and non-contiguous dermatological condition that impacts a huge global population. Pruritus, inflammation, numerous eczematous lesions, and an unpredictable progression are the hallmark characteristics of this dermatological complication. Despite its multifactorial and incompletely comprehended pathophysiology, AD appears from a combined cause of environmental and genetic factors that lead to epidermal barrier integrity, oxidative stress, and immune system imbalance at both the skin and systemic levels.Areas covered: The lipid nanocarrier (LN), referred to as the vesicular system, has become a focal point of interest among researchers striving to develop novel formulations that improve therapeutic efficacy, avoid off-target effects, prevent premature drug degradation, and increase the safety profile of drugs by different surface modification methods. Hence, LNs are categorized into hard-LNs with hardened surfaces and soft-LNs that can alter their size during distribution in the body for delivering both lipophilic and hydrophilic drugs topically.Expert opinion: In the last two decades, numerous clinical studies have clearly shown the therapeutic relevance of specialized LNs and hybrid systems for effectively managing AD and halting its progression with improved quality of patient life, supporting the therapeutic superiority of advanced LN-mediated interventions compared to traditional treatment modalities.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1-21"},"PeriodicalIF":5.4,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148521755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Functional paradigm evolution in microneedle materials: design strategies, performance trade-offs, and translational challenges. 微针材料的功能范式演变：设计策略、性能权衡和转化挑战。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-10-01 Epub Date: 2026-08-12 DOI: 10.1080/17425247.2026.2713662

Langlin Ji, Lina Du

{"title":"Functional paradigm evolution in microneedle materials: design strategies, performance trade-offs, and translational challenges.","authors":"Langlin Ji, Lina Du","doi":"10.1080/17425247.2026.2713662","DOIUrl":"10.1080/17425247.2026.2713662","url":null,"abstract":"Introduction: Microneedles (MNs) have emerged as a versatile platform for transdermal delivery, enabling minimally invasive administration of small molecules and biologics. As their performance is fundamentally determined by material properties, continuous innovation in MN materials has been central to the evolution of the field.Areas covered: Relevant literature published from 2020 to 2026 is surveyed using Web of Science and PubMed. This review analyzes MN materials using a functional paradigm framework covering structural carriers, controlled-release carriers, intelligent integrated carriers, and emerging all-drug glassy systems. It compares representative materials by design rationale, advantages, limitations, and trade-offs among drug loading, release control, and biocompatibility, and highlights recent advances together with major challenges to clinical translation.Expert opinion: Current progress suggests that MN material design is shifting from proof-of-concept innovation toward translation-oriented optimization. Increasing functionality alone is unlikely to ensure clinical impact unless it is accompanied by reproducibility, manufacturability, safety, and application-specific performance. Future advances will likely depend on simplified high-performance material systems, more predictable responsive release, and drug-specific designs that better balance loading capacity, release precision, and biocompatibility.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1819-1836"},"PeriodicalIF":5.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148715093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multifunctional lipid nanocarriers: advancing topical skin cancer treatment. 多功能脂质纳米载体：促进局部皮肤癌治疗。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-10-01 Epub Date: 2026-08-25 DOI: 10.1080/17425247.2026.2724073

Lívia Vieira Depieri, Milena Finazzi Morais, Lorena Amorim Tiritan, Lara Marques Amaral, Letícia Maria da Silva Fernandes, Maria Vitória Lopes Badra Bentley

{"title":"Multifunctional lipid nanocarriers: advancing topical skin cancer treatment.","authors":"Lívia Vieira Depieri, Milena Finazzi Morais, Lorena Amorim Tiritan, Lara Marques Amaral, Letícia Maria da Silva Fernandes, Maria Vitória Lopes Badra Bentley","doi":"10.1080/17425247.2026.2724073","DOIUrl":"10.1080/17425247.2026.2724073","url":null,"abstract":"Introduction: Skin cancer is among the most prevalent cancers worldwide and represents a substantial clinical and economic burden. Although topical therapy offers localized treatment and reduced systemic toxicity, its effectiveness is often limited by poor skin penetration, inadequate drug retention, and the complexity of the tumor microenvironment. These limitations have driven the development of multifunctional lipid nanocarriers that integrate therapeutic and delivery strategies within a single platform, offering opportunities to simultaneously address biological barriers and therapeutic targets and improve topical skin cancer treatment.Areas covered: This review discusses advances in multifunctional lipid nanocarriers for topical skin cancer treatment, focusing on surface functionalization, stimulus-responsive systems, combination therapies, theranostic platforms, and physical delivery-assisted approaches. PubMed, Scopus, and Web of Science were searched through July 2026 without an initial date restriction. The biological rationale and potential of these strategies to improve drug delivery, tumor selectivity, and therapeutic efficacy are discussed.Expert opinion: Multifunctional lipid nanocarriers offer a versatile platform for addressing limitations of conventional skin cancer therapies. Integrating complementary functionalities can enhance therapeutic performance by targeting multiple biological and delivery-related barriers. Future progress will rely on identifying combinations that provide meaningful therapeutic advantages while remaining compatible with manufacturing, regulatory, and clinical requirements.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1889-1909"},"PeriodicalIF":5.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148803567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical insights: an update on transmucosal absorption with a focus on dodecyl maltoside. 临床见解：更新的跨粘膜吸收与重点十二烷基麦芽糖苷。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-10-01 Epub Date: 2026-08-12 DOI: 10.1080/17425247.2026.2713668

Adrian L Rabinowicz, Stuart Madden, Enrique Carrazana

{"title":"Clinical insights: an update on transmucosal absorption with a focus on dodecyl maltoside.","authors":"Adrian L Rabinowicz, Stuart Madden, Enrique Carrazana","doi":"10.1080/17425247.2026.2713668","DOIUrl":"10.1080/17425247.2026.2713668","url":null,"abstract":"Introduction: Nasal administration provides a favorable option for patients with a variety of disease conditions and their caregivers, including for acute treatment therapies in the community setting. This noninvasive route of administration allows for device portability and quick access, absorption, and bioavailability. Drug products should be developed with an understanding of ideal formulation characteristics and device criteria to ensure high bioavailability, effectiveness, and tolerability.Areas covered: This narrative review examines how intranasal administration addresses limitations associated with some other routes of administration and how its unique limitations can be addressed. There are numerous strategies to increase mucosal absorption, such as mucoadhesion and permeation enhancement. PubMed was searched for excipient dodecyl maltoside (DDM) in transmucosal absorption; those results were used for subsequent research. We discuss DDM use in formulations approved by several health authorities worldwide, including the US Food and Drug Administration, and in investigational drugs.Expert opinion: DDM has demonstrated benefits in enhancing absorption in nasal spray formulations across a broad spectrum of medical conditions. These new treatment options offer effectiveness and ease of use for patients and caregivers. DDM and closely related excipients have many promising opportunities for future applications, facilitating absorption across nasal and other epithelial membranes.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1863-1875"},"PeriodicalIF":5.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148703141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Developing next-generation antibody-drug conjugates for breast cancer drug delivery: hurdles and advances in the clinic. 开发用于乳腺癌药物传递的下一代抗体-药物偶联物：临床中的障碍和进展。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-10-01 Epub Date: 2026-08-11 DOI: 10.1080/17425247.2026.2713673

Callum Chapman, Anthony Cheung, Georgina B Armstrong, Sophia N Karagiannis, Zahra Rattray

{"title":"Developing next-generation antibody-drug conjugates for breast cancer drug delivery: hurdles and advances in the clinic.","authors":"Callum Chapman, Anthony Cheung, Georgina B Armstrong, Sophia N Karagiannis, Zahra Rattray","doi":"10.1080/17425247.2026.2713673","DOIUrl":"10.1080/17425247.2026.2713673","url":null,"abstract":"Introduction: Breast cancer remains a leading cause of mortality among women worldwide, with diagnoses projected to reach 3.5 million annually by 2050. Therapeutic progress is hindered by marked molecular heterogeneity and distinct biological and clinical subtypes. Antibody-drug conjugates (ADCs) have emerged as a promising strategy for treatment‑resistant disease, combining targeted delivery with potent cytotoxic payloads.Areas covered: This review synthesizes literature spanning 1990-2026 on advances in ADC design and their clinical and translational implementation in breast cancer. Primary research articles were then inputted into Research Rabbit to identify additional original research articles and maximize data retrieval.Expert opinion: The success of ADCs is limited less by payload potency than by delivery biology. Efficacy depends on patient context, tumor site-specific factors, and bystander effects in antigen‑heterogeneous environments. However, current development often overlooks systemic antigen sinks, metastatic microenvironments, and evolving resistance. Traditional ADCs rely on a narrow range of tumor antigens and payloads, restricting therapeutic index and applicability. Future progress requires reframing antigen selection as a system-level challenge, supported by delivery-focused engineering, precision-medicine-driven trial design, and adaptive methodology.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1761-1774"},"PeriodicalIF":5.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148664902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent advances in coated and dissolving microneedle technologies for clinical translation. 用于临床翻译的包被和溶解微针技术的最新进展。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-10-01 Epub Date: 2026-08-25 DOI: 10.1080/17425247.2026.2723071

Supason Wanichwecharungruang, Supanan Ampawa

{"title":"Recent advances in coated and dissolving microneedle technologies for clinical translation.","authors":"Supason Wanichwecharungruang, Supanan Ampawa","doi":"10.1080/17425247.2026.2723071","DOIUrl":"10.1080/17425247.2026.2723071","url":null,"abstract":"Introduction: Despite decades of research, no FDA-approved coated or dissolving microneedles currently exist for therapeutics or vaccines. Clinical translation requires aligning biophysical delivery mechanisms with product-specific regulatory and biopharmaceutical standards.Area covered: This review analyzes critical design bottlenecks, including the skin's elastic recoil, the needle bouncing-out challenge, skin penetration, variation of tissue hydration, and prolonged micro-channel patency. We examine progress in high-density coated and tip-loaded microneedles paired with mechanical applicators, alongside needle-detachable designs that decouple drug delivery from needle dissolution. We highlight the necessity of targeting micro-dose payloads, such as hormones and vaccines, to overcome the inherent geometric volume limitations of microneedles.Expert opinion: Bridging microneedle designs with clinical applications and regulatory requirements is essential. High-density coated microneedles provide more surface area to accommodate fast dissolution of the thin payload coating and, when paired with an applicator, can circumvent the skin penetration challenges. Loading drug at the tips of dissolving microneedles offers fast dissolution due to deep tip penetration, while detachable architectures, particularly active fluid-triggered systems, offer solutions to the variabilities of skin hydration and elastic recoil. Micro-dose vaccines represent a promising near-term application; their threshold-based immunology accommodates the limited volumetric capacity of microneedles while enabling dose sparing.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1877-1888"},"PeriodicalIF":5.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148803626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Addressing the needs for large-volume subcutaneous drug delivery: the case for on-body wearable injectors. 解决大容量皮下给药的需求：身上可穿戴注射器的案例。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-10-01 Epub Date: 2026-09-18 DOI: 10.1080/17425247.2026.2725755

Ronald J Pettis

{"title":"Addressing the needs for large-volume subcutaneous drug delivery: the case for on-body wearable injectors.","authors":"Ronald J Pettis","doi":"10.1080/17425247.2026.2725755","DOIUrl":"10.1080/17425247.2026.2725755","url":null,"abstract":"Introduction: The growth of biologic therapies has accelerated demand for large-volume subcutaneous delivery systems that are clinically feasible, patient-friendly, and suitable for assisted administration or self-administration outside a controlled clinical environment. For patients, subcutaneous delivery can reduce lengthy treatment times, disruptions to daily life, and resulting expenses. For healthcare systems, it can alleviate overburdening to providers by simplifying or decreasing lengthy in-clinic delivery. The transition to subcutaneous dosing of drugs with larger volumes and higher viscosities, however, has necessitated new delivery devices.Areas covered: This critical perspective: (1) explores the crowded device landscape, noting the key benefits and tradeoffs for delivery methods, (2) surveys the state of the on-body injector field, highlighting commercial and in-development systems, their strengths, and potential drawbacks, and (3) proposes key strategic imperatives for developing large-volume subcutaneous delivery devices. In closing, a perspective on the field addresses the positioning of on-body injector systems against key competitors, and the inherent risk-sharing between device and pharmaceutical developers to build evidence for large-volume subcutaneous delivery systems.Expert opinion: The maturation of large-volume subcutaneous delivery technologies signals a fundamental shift in biologic administration, and on-body injectors are uniquely positioned to bridge usability, volume capability, and at-home capability.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1745-1760"},"PeriodicalIF":5.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148901818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Synthesis strategies and functional properties of polysaccharide hydrogels for controlled drug delivery applications. 控制给药用多糖水凝胶的合成策略及功能性质。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-10-01 Epub Date: 2026-08-19 DOI: 10.1080/17425247.2026.2712528

Gioconda Millotti, Flavia Laffleur, Agnes Kestler

{"title":"Synthesis strategies and functional properties of polysaccharide hydrogels for controlled drug delivery applications.","authors":"Gioconda Millotti, Flavia Laffleur, Agnes Kestler","doi":"10.1080/17425247.2026.2712528","DOIUrl":"10.1080/17425247.2026.2712528","url":null,"abstract":"Introduction: Polysaccharide hydrogels have gained increasing attention as innovative platforms for controlled and stimuli-responsive drug delivery. Inherent biocompatibility, biodegradability and chemical versatility of these materials render them particularly well-suited for biomedical applications. Moreover, their ability to be engineered into 'smart' systems facilitates controlled release of therapeutic agents at target sites. This review summarizes recent advances in synthesis strategies and functional properties of polysaccharide hydrogels relevant for drug delivery.Areas covered: Mechanical tunability, responsiveness to physiological stimuli and affinity-based interactions are analyzed with regards to their impact on therapeutic efficacy. Key hurdles such as manufacturing scalability, reproducibility, regulatory compliance, challenge of balancing biodegradability with mechanical stability and controlled drug release are critically discussed. Proof-of-concept studies are highlighted spanning preclinical in vivo models, as well as early clinical trials exploring application in oncology, regenerative medicine and pain management.Expert opinion: Polysaccharide-based stimuli-responsive and multifunctional hydrogels represent highly promising platforms for controlled and targeted drug delivery. While recent advances in biofabrication and nanotechnology have significantly expanded their therapeutic potential, important challenges including scalability, reproducibility, and clinical translation, still need to be addressed. In particular, limited availability of long-term in vivo safety and efficacy data remains a major barrier to broader clinical application.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1795-1817"},"PeriodicalIF":5.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148803560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimizing delivery to the gastrointestinal tract: a mechanistic approach to nutraceutical design and development. 优化输送到胃肠道：营养保健品设计和开发的机械方法。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-10-01 Epub Date: 2026-08-19 DOI: 10.1080/17425247.2026.2719683

Alex Hunter, Amin Ariaee, Anthony Wignall, Kara Paxton, Kristen Bremmell, Clive Prestidge, Paul Joyce

{"title":"Optimizing delivery to the gastrointestinal tract: a mechanistic approach to nutraceutical design and development.","authors":"Alex Hunter, Amin Ariaee, Anthony Wignall, Kara Paxton, Kristen Bremmell, Clive Prestidge, Paul Joyce","doi":"10.1080/17425247.2026.2719683","DOIUrl":"10.1080/17425247.2026.2719683","url":null,"abstract":"Introduction: Nutraceuticals have garnered increasing scientific and commercial interest for their potential roles in health promotion, disease prevention and adjunctive disease management. However, the complex physicochemical and biological environment of the gastrointestinal (GI) tract presents formidable barriers to their effective oral delivery, contributing to a persistent gap between preclinical promise and clinical efficacy. A mechanistic understanding of GI physiology, nutraceutical-specific delivery challenges and available formulation strategies is therefore essential to advance the field.Areas covered: Preclinical and clinical studies exploring the oral delivery of nutraceuticals were identified through targeted PubMed, Scopus and Web of Science searches to examine the GI tract as a dynamic delivery environment. Nutraceuticals are classified according to their primary delivery challenges, including lipophilicity, chemical and enzymatic lability and requirements for colon-targeted or microbiome-directed delivery. Formulation strategies are reviewed mechanistically, with particular attention to lipid-based systems, polymeric nanoparticles, hydrogel and hybrid biomaterials and colon-targeted delivery platforms.Expert opinion: Advancing nutraceutical science requires moving toward a formulation-driven approach to overcome the biological barriers faced by oral delivery. There is a critical need for regulatory oversight to ensure that marketed claims are backed by scientific evidence relating to nutraceutical pharmacokinetics, pharmacodynamics and safety evaluations.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1837-1861"},"PeriodicalIF":5.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148764446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunoliposomes in breast cancer drug delivery: utilizing superparamagnetic iron oxide nanoparticles. 免疫脂质体在乳腺癌药物传递中的应用：利用超顺磁性氧化铁纳米颗粒。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-10-01 Epub Date: 2026-08-14 DOI: 10.1080/17425247.2026.2718166

Jessyca Aparecida Paes Dutra, Mariana Conceição, Allana Carolina Leme de Almeida, Izabella Maria Pereira Silva Tegon, Vinycius Fernandes da Rocha, Marlus Chorilli

{"title":"Immunoliposomes in breast cancer drug delivery: utilizing superparamagnetic iron oxide nanoparticles.","authors":"Jessyca Aparecida Paes Dutra, Mariana Conceição, Allana Carolina Leme de Almeida, Izabella Maria Pereira Silva Tegon, Vinycius Fernandes da Rocha, Marlus Chorilli","doi":"10.1080/17425247.2026.2718166","DOIUrl":"10.1080/17425247.2026.2718166","url":null,"abstract":"Introduction: Immunoliposomes (ILs) allow selective interaction with cells by antibodies or their fragments. When associated with superparamagnetic iron oxide nanoparticles (SPIONs), they form immunomagnetoliposomes (IMLs) that enable targeting, drug-release triggers, thermal ablation, and imaging, allowing real-time observation, therapy response, and patient stratification.Areas covered: This study is about the development and application of antibody and fragment conjugates in SPION-loaded liposomes as a multifunctional platform to overcome the disadvantages of conventional therapies for breast cancer (BC), including an overview of clinical trials with ILs and the prospects for IMLs. The databases searched include PubMed, Scopus, Google Scholar, Clinicaltrials.gov, and reports by regulatory agencies, focusing on articles from the period 2015-2026.Expert opinion: IML's advantages do not represent a definitive solution but may partially mitigate the uncertainties associated with BC therapy. Its impact consists of its ability to enable clinical therapies in a controlled, monitored manner. The clinical failures of two of three clinical trials involving antibody-directed liposomes (NCT02833766 and NCT02213744) demonstrate the need for IMLs as versatile systems that more effectively overcome the therapeutic limitations of accumulation and penetration in solid tumors associated with ILs.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1775-1793"},"PeriodicalIF":5.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148715135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0